This week the results of Esaote, Labiana, Chiesi, Eli Lilly, Pfizer and Novo Nordisk have already been published, which continues its unstoppable rise due to the sales of its antidiabetics. Roche and Novartis receive the green light from the regulator for new drugs and LEO Pharma and Faes Farma renew their addresses.
MONDAY
ESAOTE
The company specialized in medical diagnosis systems and MRI techniques increases its turnover by 6.5%, up to 273 million euros.
ROCHE
The Swiss laboratory obtains a positive assessment from the EU for its injection against multiple sclerosis.
LABIANA
The pharmaceutical company listed on BME Growth increases its turnover to 58.5 million in 2023.
NOVARTIS
The Swiss multinational receives the green light for a solution for pediatric patients with tumors.
CHIESI
The biopharmaceutical group exceeds 3,000 million euros in turnover in 2023.
MIKROBIOMIK
Caixabank leads a round to raise up to ten million for the Biscayan biopharmaceutical company.
TUESDAY
LAMINATE PHARMA
The Balearic laboratory, hunting for buyers in Europe for its new anti-tumor drug.
GRIFOLS
Berenberg cuts the potential of the Catalan company by 23%, but continues to bet on its shares.
ELI LILLY
The pharmacy US exceeds first quarter estimates and increases its 2024 targets.
LEO PHARMA
The pharmaceutical company, dedicated to developing medications for thrombosis and dermatological solutions, adds Isabel Betoret to its team.
WEDNESDAY
GRIFOLS
The multinational blood products company closes the issuance of one billion in bonds and highlights the confidence of the markets.
PFIZER
The American pharmaceutical company fell 20% in sales and 44% in profits due to the drop in Covid-19 products.
THURSDAY
NOVO NORDISK
The Danish multinational earned 3,406 in the first quarter, 28% more.
FAES PHARMA
The Spanish company proposes Eduardo Recoder de la Cuadra as executive director.
FRIDAY
FRESENIUS KABI
The health products division of the German multinational sells its rehabilitation business to PAI Partners for 853 million euros.
